These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34216284)

  • 1. Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).
    Rael CT; Lopez-Ríos J; McKenna SA; Das D; Dolezal C; Abascal E; Carballo-Diéguez A; Schnall R; Hope TJ; Bauermeister J; Bockting W
    AIDS Behav; 2021 Dec; 25(12):4180-4192. PubMed ID: 34216284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
    Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
    N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
    J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.
    Fonner VA; Ridgeway K; van der Straten A; Lorenzetti L; Dinh N; Rodolph M; Schaefer R; Schmidt HA; Nguyen VTT; Radebe M; Peralta H; Baggaley R
    AIDS; 2023 May; 37(6):957-966. PubMed ID: 36723489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs).
    Rael CT; Martinez M; Giguere R; Bockting W; MacCrate C; Mellman W; Valente P; Greene GJ; Sherman SG; Footer KHA; D'Aquila RT; Carballo-Diéguez A; Hope TJ
    AIDS Behav; 2020 May; 24(5):1452-1462. PubMed ID: 31654172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China.
    Liu L; Ruan Y; Chen S; Tang H; Liu J; Jiang Y; Pei H; Huang T; Lan G; Xie Y
    Arch Sex Behav; 2024 Jul; 53(7):2795-2806. PubMed ID: 38849704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study.
    Smith JA; Garnett GP; Hallett TB
    J Infect Dis; 2021 Oct; 224(7):1179-1186. PubMed ID: 32492704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
    Kerrigan D; Mantsios A; Grant R; Markowitz M; Defechereux P; La Mar M; Beckham SW; Hammond P; Margolis D; Murray M
    AIDS Behav; 2018 Nov; 22(11):3540-3549. PubMed ID: 29290075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
    Durham SH; Milam A; Waer D; Chahine EB
    Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable cabotegravir for the prevention of HIV infection.
    Clement ME; Kofron R; Landovitz RJ
    Curr Opin HIV AIDS; 2020 Jan; 15(1):19-26. PubMed ID: 31644481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon G; Ghosn J
    HIV Med; 2023 Jun; 24(6):653-663. PubMed ID: 36468218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants.
    Johnson LF; Myer L; Jamieson L; Meyer-Rath G; Delany-Moretlwe S; Joseph Davey D
    AIDS; 2024 Mar; 38(4):589-594. PubMed ID: 38016171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
    Bares SH; Scarsi KK
    Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Fogel JM; Wang Z; Piwowar-Manning E; Kofron R; Moser A; Bhandari P; Gollings R; Bushman LR; Weng L; Halvas EK; Mellors J; Anderson PL; Persaud D; Hendrix CW; McCauley M; Rinehart AR; St Clair M; Ford SL; Rooney JF; Adeyeye A; Chariyalertsak S; Mayer K; Arduino RC; Cohen MS; Grinsztejn B; Hanscom B; Landovitz RJ; Eshleman SH
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0005323. PubMed ID: 36995219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.